GDTC
CytoMed Therapeutics Limited
Price Chart
Latest Quote
$1.00
-0.08 (-7.78%)
Current Price
| Previous Close | $1.08 |
| Open | $1.00 |
| Day High | $1.00 |
| Day Low | $1.00 |
| Volume | 448 |
Stock Information
Note: Financial values converted from SGD to USD
| Shares Outstanding | 11.83M |
| Total Debt | $372K |
| Cash Equivalents | $1.62M |
| Revenue | $664K |
| Net Income | $-3.07M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $11.95M |
| EPS (TTM) | $-0.26 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.64M |
| Sales | $664K |
| Income | $-3.07M |
| Book/sh | $0.43 |
| Cash/sh | $0.18 |
| Employees | 42 |
Financial Ratios
| Quick Ratio | 3.14 |
| Current Ratio | 5.17 |
| Debt/Eq | 7.04 |
Returns & Margins
| ROA | -29.31% |
| ROE | -50.28% |
| Gross Margin | 89.57% |
| Operating Margin | -535.25% |
Ownership
| Insider Ownership | 68.78% |
| Institutional Ownership | 0.18% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.73 |
| P/S | 13.88 |
| P/B | 2.36 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.13 |
| SMA50 | $1.05 |
| SMA200 | $1.42 |
| RSI | 39.17 |
| ATR | 0.0991 |
| Shares Float | 3.91M |
| Short Float | 1.94% |
| Short Ratio | 2.50 |
| Volatility | -0.04 |
| Rel Volume | 0.12 |
Performance History
| Week | -12.17% |
| Month | -17.21% |
| Quarter | -1.94% |
| 6 Months | -35.26% |
| YTD | -27.34% |
| Year | -55.70% |
| 3 Years | -64.44% |
| 10 Years | -74.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $1.01 | 2,030 |
| 2026-06-22 | $1.08 | 2,200 |
| 2026-06-18 | $1.08 | 0 |
| 2026-06-17 | $1.08 | 2,400 |
| 2026-06-16 | $1.11 | 1,600 |
| 2026-06-15 | $1.15 | 4,200 |
| 2026-06-12 | $1.14 | 3,400 |
| 2026-06-11 | $1.07 | 118,500 |
| 2026-06-10 | $1.07 | 2,800 |
| 2026-06-09 | $1.14 | 3,600 |
| 2026-06-08 | $1.15 | 126,000 |
| 2026-06-05 | $1.29 | 13,900 |
| 2026-06-04 | $1.18 | 3,700 |
| 2026-06-03 | $1.18 | 1,400 |
| 2026-06-02 | $1.14 | 500 |
| 2026-06-01 | $1.14 | 2,700 |
| 2026-05-29 | $1.17 | 23,600 |
| 2026-05-28 | $1.14 | 7,600 |
| 2026-05-27 | $1.20 | 2,300 |
| 2026-05-26 | $1.15 | 13,300 |
About CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $52,695 | $13,269 | $0 | $0 |
| Cost Of Revenue | $52,695 | $13,269 | $0 | $0 |
| Total Revenue | $251,404 | $53,864 | $0 | $0 |
| Operating Revenue | $251,404 | $53,864 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $16,202 | $15,743 | $39,744 | $97,012 |
| Total Expenses | $3,538,762 | $2,480,066 | $2,978,258 | $1,438,864 |
| Rent Expense Supplemental | $4,082 | $2,492 | $1,320 | $1,706 |
| Other Income Expense | $110,323 | $241,269 | $-406,191 | $-891,396 |
| Other Non Operating Income Expenses | $6,528 | - | $-76,536 | $-845,137 |
| Net Non Operating Interest Income Expense | $79,820 | $230,456 | $181,692 | $-95,387 |
| Interest Expense Non Operating | $16,202 | $15,743 | $39,744 | $97,012 |
| Operating Expense | $3,486,068 | $2,466,797 | $2,978,258 | $1,438,864 |
| Other Operating Expenses | $156,159 | $-95,414 | $665,196 | $-141,131 |
| Selling And Marketing Expense | $42,141 | $18,431 | $25,813 | $0 |
| General And Administrative Expense | $1,386,068 | $962,496 | $969,410 | $307,766 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,084,908 | $-1,950,475 | $-3,203,050 | $-2,426,729 |
| Net Interest Income | $79,820 | $230,456 | $181,692 | $-95,387 |
| Interest Income | $96,023 | $246,199 | $221,436 | $1,625 |
| Normalized Income | $-3,193,657 | $-2,181,077 | $-2,949,505 | $-2,409,913 |
| Net Income From Continuing And Discontinued Operation | $-3,084,908 | $-1,950,475 | $-3,203,050 | $-2,426,729 |
| Net Income Common Stockholders | $-3,084,908 | $-1,950,475 | $-3,203,050 | $-2,426,729 |
| Net Income | $-3,084,908 | $-1,950,475 | $-3,203,050 | $-2,426,729 |
| Net Income Including Noncontrolling Interests | $-3,097,215 | $-1,954,476 | $-3,203,263 | $-2,426,918 |
| Net Income Continuous Operations | $-3,097,215 | $-1,954,476 | $-3,203,263 | $-2,426,918 |
| Pretax Income | $-3,097,215 | $-1,954,476 | $-3,202,757 | $-2,425,647 |
| Special Income Charges | $221,443 | $0 | $0 | $217 |
| Earnings From Equity Interest | $-4,953 | $10,668 | $-24,179 | $-25,999 |
| Interest Income Non Operating | $96,023 | $246,199 | $221,436 | $1,625 |
| Operating Income | $-3,287,358 | $-2,426,202 | $-2,978,258 | $-1,438,864 |
| Depreciation Amortization Depletion Income Statement | $175,770 | $94,861 | $80,642 | $86,605 |
| Depreciation And Amortization In Income Statement | $175,770 | $94,861 | $80,642 | $86,605 |
| Amortization Of Intangibles Income Statement | $23,173 | $9,732 | $1,695 | $1,938 |
| Depreciation Income Statement | $152,597 | $85,129 | $78,948 | $84,667 |
| Gross Profit | $198,710 | $40,595 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | - | - | $-0.30 | $-0.22 |
| Basic EPS | - | - | $-0.30 | $-0.22 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-51,931 | $-3,444 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,878,528 | $-1,909,424 | $-2,562,141 | $-2,003,897 |
| Total Unusual Items | $108,748 | $230,601 | $-305,476 | $-20,260 |
| Total Unusual Items Excluding Goodwill | $108,748 | $230,601 | $-305,476 | $-20,260 |
| Reconciled Depreciation | $311,233 | $259,911 | $295,395 | $304,477 |
| EBITDA (Bullshit earnings) | $-2,769,779 | $-1,678,823 | $-2,867,618 | $-2,024,157 |
| EBIT | $-3,081,012 | $-1,938,734 | $-3,163,013 | $-2,328,634 |
| Diluted NI Availto Com Stockholders | $-3,084,908 | $-1,950,475 | $-3,203,050 | $-2,426,729 |
| Minority Interests | $12,306 | $4,001 | $212 | $188 |
| Tax Provision | $0 | $0 | $506 | $1,271 |
| Gain On Sale Of Business | $228,037 | $0 | $0 | - |
| Impairment Of Capital Assets | $6,594 | $0 | $0 | - |
| Gain On Sale Of Security | $-112,695 | $230,601 | $-305,476 | $-20,477 |
| Other Taxes | $7,341 | $6,519 | $5,162 | $5,460 |
| Amortization | $23,173 | $9,732 | $1,695 | $1,938 |
| Research And Development | $1,718,589 | $1,479,903 | $1,232,034 | $1,180,164 |
| Selling General And Administration | $1,428,209 | $980,928 | $995,224 | $307,766 |
| Other Gand A | $362,444 | $406,882 | $396,952 | $142,799 |
| Insurance And Claims | $0 | $73,136 | $219,172 | $0 |
| Rent And Landing Fees | $4,082 | $2,492 | $1,320 | $1,706 |
| Salaries And Wages | $1,019,543 | $479,987 | $351,967 | $163,262 |
| Gain On Sale Of Ppe | - | $0 | $0 | $217 |
| Diluted Average Shares | - | - | $8,238,661 | $8,478,508 |
| Basic Average Shares | - | - | $8,238,661 | $8,478,508 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,975,240 | $6,876,688 | $8,705,493 | $440,340 |
| Total Assets | $6,188,447 | $7,802,642 | $9,586,042 | $4,051,041 |
| Total Non Current Assets | $3,349,592 | $3,152,016 | $1,761,016 | $2,118,264 |
| Non Current Accounts Receivable | $377,650 | $387,507 | - | - |
| Investmentin Financial Assets | $14,113 | $0 | - | - |
| Goodwill And Other Intangible Assets | $96,795 | $72,115 | $9,620 | $14,577 |
| Other Intangible Assets | $96,519 | $71,840 | $9,345 | $14,302 |
| Current Assets | $2,838,855 | $4,650,626 | $7,825,026 | $1,932,777 |
| Prepaid Assets | $1,112,479 | $704,587 | $695,045 | $663,847 |
| Receivables | $102,344 | $93,938 | $158,682 | $44,627 |
| Other Receivables | $16,901 | $48,921 | $10,314 | $44,627 |
| Taxes Receivable | $4,066 | $2,241 | $3,650 | - |
| Accrued Interest Receivable | $884 | $28,219 | $144,718 | - |
| Accounts Receivable | $80,492 | $14,556 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $1,624,032 | $3,852,102 | $6,971,299 | $1,224,303 |
| Cash And Cash Equivalents | $1,624,032 | $3,852,102 | $6,971,299 | $1,224,303 |
| Cash Financial | $1,624,032 | $3,852,102 | $6,971,299 | $1,224,303 |
| Debt | ||||
| Total Debt | $373,992 | $359,025 | $347,223 | $3,269,985 |
| Long Term Debt And Capital Lease Obligation | $327,146 | $323,443 | $316,029 | $368,547 |
| Long Term Debt | $285,713 | $305,596 | $316,029 | $363,347 |
| Current Debt And Capital Lease Obligation | $46,846 | $35,582 | $31,194 | $2,901,438 |
| Current Debt | $31,657 | $29,179 | $26,293 | $2,895,463 |
| Other Current Borrowings | $31,657 | $29,179 | $26,293 | $2,895,463 |
| Net Debt | - | - | - | $2,034,507 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $876,762 | $793,583 | $871,669 | $3,596,652 |
| Total Non Current Liabilities Net Minority Interest | $327,146 | $323,443 | $316,029 | $368,547 |
| Current Liabilities | $549,616 | $470,140 | $555,641 | $3,228,105 |
| Other Current Liabilities | $19,425 | $9,258 | $113,627 | - |
| Current Deferred Liabilities | $141,678 | $84,593 | $6,510 | $7,056 |
| Payables And Accrued Expenses | $341,667 | $340,708 | $404,309 | $319,611 |
| Payables | $146,070 | $58,843 | $58,162 | $136,777 |
| Other Payable | $47,336 | $28,902 | $39,082 | $123,223 |
| Total Tax Payable | $2,058 | $0 | $0 | $1,237 |
| Accounts Payable | $96,677 | $29,941 | $19,079 | $11,337 |
| Equity | ||||
| Common Stock Equity | $5,072,034 | $6,948,803 | $8,715,114 | $454,917 |
| Total Equity Gross Minority Interest | $5,311,685 | $7,009,059 | $8,714,373 | $454,389 |
| Stockholders Equity | $5,072,034 | $6,948,803 | $8,715,114 | $454,917 |
| Other Equity Interest | $86,201 | - | $57,297 | - |
| Gains Losses Not Affecting Retained Earnings | $468,809 | $15,675 | $-168,490 | $-98,802 |
| Other Equity Adjustments | $408,146 | $57,337 | - | - |
| Retained Earnings | $-14,592,414 | $-11,507,506 | $-9,557,031 | $-6,353,981 |
| Long Term Equity Investment | $0 | $171,239 | $151,184 | $185,557 |
| Other | ||||
| Ordinary Shares Number | $9,167,198 | $8,943,657 | $8,935,386 | $8,478,508 |
| Share Issued | $9,167,198 | $8,943,657 | $8,935,386 | $8,478,508 |
| Tangible Book Value | $4,975,240 | $6,876,688 | $8,705,493 | $440,340 |
| Invested Capital | $5,389,405 | $7,283,578 | $9,057,436 | $3,713,728 |
| Working Capital | $2,289,240 | $4,180,486 | $7,269,385 | $-1,295,328 |
| Capital Lease Obligations | $56,622 | $24,250 | $4,901 | $11,175 |
| Total Capitalization | $5,357,748 | $7,254,398 | $9,031,142 | $818,265 |
| Minority Interest | $239,650 | $60,257 | $-741 | $-529 |
| Foreign Currency Translation Adjustments | $60,663 | $-41,662 | $-168,490 | $-98,802 |
| Capital Stock | $19,109,439 | $18,440,634 | $18,383,337 | $6,907,700 |
| Common Stock | $19,109,439 | $18,440,634 | $18,383,337 | $6,907,700 |
| Long Term Capital Lease Obligation | $41,433 | $17,847 | $0 | $5,200 |
| Current Deferred Revenue | $141,678 | $84,593 | $6,510 | $7,056 |
| Current Capital Lease Obligation | $15,189 | $6,403 | $4,901 | $5,975 |
| Current Accrued Expenses | $195,597 | $281,865 | $346,147 | $182,833 |
| Investments And Advances | $14,113 | $171,239 | $151,184 | $185,557 |
| Available For Sale Securities | $14,113 | - | - | - |
| Investmentsin Associatesat Cost | $0 | $171,239 | $151,184 | $185,557 |
| Goodwill | $275 | $275 | $275 | $275 |
| Net PPE | $2,861,034 | $2,521,155 | $1,600,212 | $1,918,130 |
| Accumulated Depreciation | $-1,710,732 | $-1,369,353 | $-1,057,656 | $-815,875 |
| Gross PPE | $4,571,766 | $3,890,508 | $2,657,868 | $2,734,005 |
| Other Properties | $2,108,780 | $1,542,767 | $1,291,617 | $1,318,817 |
| Machinery Furniture Equipment | $397,362 | $347,054 | $255,913 | $260,407 |
| Buildings And Improvements | $1,591,614 | $1,544,947 | $821,873 | $848,739 |
| Land And Improvements | $474,011 | $455,740 | $288,465 | $306,042 |
| Properties | $0 | $0 | $0 | $0 |
| Dueto Related Parties Current | - | - | $0 | $980 |
| Duefrom Related Parties Current | - | - | - | $0 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,410,522 | $-3,258,440 | $-2,781,904 | $-1,450,984 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,865,584 | $-2,100,232 | $-2,736,725 | $-1,083,786 |
| Cash Flow From Continuing Operating Activities | $-2,865,584 | $-2,100,232 | $-2,736,725 | $-1,083,786 |
| Operating Gains Losses | $-168,117 | $-130,272 | $195,698 | $8,997 |
| Investing Activities | ||||
| Capital Expenditure | $-544,938 | $-1,158,208 | $-45,179 | $-367,198 |
| Investing Cash Flow | $720,207 | $873,085 | $-2,116,414 | $-366,818 |
| Cash Flow From Continuing Investing Activities | $720,207 | $873,085 | $-2,116,414 | $-366,818 |
| Net Other Investing Changes | $-15,907 | $-387,507 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $219,402 | $0 | $8,763,097 | $947,570 |
| Financing Cash Flow | $161,705 | $-50,292 | $8,463,059 | $750,768 |
| Cash Flow From Continuing Financing Activities | $161,705 | $-50,292 | $8,463,059 | $750,768 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $219,402 | $0 | $8,763,097 | $947,570 |
| Common Stock Issuance | $219,402 | $0 | $8,763,097 | $947,570 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-41,494 | $-34,549 | $-263,835 | $-332,294 |
| End Cash Position | $1,624,032 | $3,640,275 | $4,823,829 | $1,224,303 |
| Beginning Cash Position | $3,640,275 | $4,823,829 | $1,224,303 | $1,947,429 |
| Effect Of Exchange Rate Changes | $-32,571 | $93,885 | $-10,394 | $-23,291 |
| Changes In Cash | $-1,983,672 | $-1,277,439 | $3,609,920 | $-699,836 |
| Interest Paid Cff | $-16,202 | $-15,743 | $-36,203 | $-97,012 |
| Net Issuance Payments Of Debt | $-41,494 | $-34,549 | $-263,835 | $-99,790 |
| Net Long Term Debt Issuance | $-41,494 | $-34,549 | $-263,835 | $-99,790 |
| Long Term Debt Payments | $-41,494 | $-34,549 | $-263,835 | $-332,294 |
| Interest Received Cfi | $125,693 | $360,821 | $76,235 | $0 |
| Net Investment Purchase And Sale | $211,827 | $1,935,643 | $-2,147,470 | $0 |
| Sale Of Investment | $211,827 | $1,935,643 | - | - |
| Net Business Purchase And Sale | $943,533 | $122,336 | $0 | $0 |
| Sale Of Business | $943,533 | $122,336 | $0 | - |
| Net Intangibles Purchase And Sale | $-50,596 | $-73,015 | $0 | $0 |
| Purchase Of Intangibles | $-50,596 | $-73,015 | $0 | $0 |
| Net PPE Purchase And Sale | $-494,342 | $-1,085,193 | $-45,179 | $-366,818 |
| Purchase Of PPE | $-494,342 | $-1,085,193 | $-45,179 | $-367,198 |
| Taxes Refund Paid | $0 | $0 | $-1,700 | $0 |
| Interest Received Cfo | $0 | $1,877 | $483 | $1,625 |
| Change In Working Capital | $-376,274 | $-46,815 | $81,313 | $85,176 |
| Change In Other Working Capital | $55,841 | $79,273 | $1,513 | $-7,741 |
| Change In Payables And Accrued Expense | $-132 | $-64,792 | $83,876 | $205,424 |
| Change In Payable | $-132 | $-64,792 | $83,876 | $205,424 |
| Change In Receivables | $-431,982 | $-61,297 | $-4,076 | $-112,508 |
| Other Non Cash Items | $-79,820 | $-230,456 | $-181,692 | $95,387 |
| Stock Based Compensation | $538,014 | $0 | $0 | - |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | $76,536 | $845,137 |
| Asset Impairment Charge | $6,594 | $0 | $0 | $1,062 |
| Depreciation Amortization Depletion | $311,233 | $259,911 | $295,395 | $304,477 |
| Depreciation And Amortization | $311,233 | $259,911 | $295,395 | $304,477 |
| Amortization Cash Flow | $23,670 | $10,229 | $4,957 | $10,230 |
| Amortization Of Intangibles | $23,670 | $10,229 | $4,957 | $10,230 |
| Depreciation | $287,563 | $249,681 | $290,438 | $294,247 |
| Earnings Losses From Equity Investments | $4,953 | $-10,668 | $24,179 | $25,999 |
| Gain Loss On Investment Securities | $10,167 | $-107,178 | $173,483 | - |
| Net Foreign Currency Exchange Gain Loss | $44,800 | $-12,426 | $-1,964 | $-16,784 |
| Gain Loss On Sale Of Business | $-228,037 | $0 | $0 | - |
| Net Income From Continuing Operations | $-3,097,215 | $-1,954,476 | $-3,202,757 | $-2,425,647 |
| Issuance Of Debt | - | $0 | $0 | $232,504 |
| Long Term Debt Issuance | - | $0 | $0 | $232,504 |
| Sale Of PPE | - | $0 | $0 | $380 |
| Gain Loss On Sale Of PPE | - | $0 | $0 | $-217 |
| Net Short Term Debt Issuance | - | - | $-232,504 | $-38,751 |
| Short Term Debt Payments | - | - | $-232,504 | $-271,255 |
| Short Term Debt Issuance | - | - | $0 | $232,504 |
| Purchase Of Investment | - | - | $-2,147,470 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
Fetched: 2026-06-21